Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors
- 1 November 2007
- journal article
- Published by Wiley in Cancer Science
- Vol. 98 (11) , 1734-1739
Abstract
The authors have previously reported that loss of heterozygosity (LOH) of the c-kit gene could be responsible for the gain in high proliferative activity in some gastrointestinal stromal tumors (GIST), resulting in enhanced metastatic potential. In the present study, an attempt was made to identify the factors that might predict the postoperative prognosis of patients with metastatic liver GIST. The clinicopathologic or genetic features of resected liver GIST in 14 patients who had undergone a hepatectomy for metachronous liver metastases and who had not received adjuvant imatinib treatment were examined. LOH of the c-kit gene was observed in seven of 12 metastatic liver GIST (58.3%), of which DNA suitable for testing could be extracted. Ten patients had recurrence after hepatectomy and four had none. The median post-recurrent disease-free survival (PRDFS) after hepatectomy was 27.5 months (range 8-104). The tumor-specific PRDFS was examined using clinicopathologic features, c-kit mutation and LOH of the c-kit gene. No single clinicopathologic or genetic finding was significantly associated with PRDFS. However, patients with 'Ki67 labeling index /=5% or LOH(+)' (P = 0.032), and there was no correlation between the presence of LOH of the c-kit gene and the Ki67 labeling index. LOH of the c-kit gene in metastatic liver seems to be a common event, and LOH of the c-kit gene in resected liver GIST may be a helpful factor in the prediction of the post-recurrent prognosis of patients with liver metastasis.Keywords
This publication has 24 references indexed in Scilit:
- Chromosomal Numerical Abnormality Profiles of Gastrointestinal Stromal TumorsJapanese Journal of Clinical Oncology, 2006
- Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumorsGastroenterology, 2003
- Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patientsGastric Cancer, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumoursThe Journal of Pathology, 2001
- Allelic Loss of 14q and 22q, NF2 Mutation, and Genetic Instability Occur Independently of c‐kit Mutation in Gastrointestinal Stromal TumorJapanese Journal of Cancer Research, 2000
- KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal TumorsThe American Journal of Pathology, 2000
- Salvage surgery for patients with recurrent gastrointestinal sarcomaCancer, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998